Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

The pseudokinase domains of guanylyl cyclase-A and -B allosterically increase the affinity of their catalytic domains for substrate.

Edmund AB, Walseth TF, Levinson NM, Potter LR.

Sci Signal. 2019 Jan 29;12(566). pii: eaau5378. doi: 10.1126/scisignal.aau5378.

PMID:
30696704
2.

Regulation of the Natriuretic Peptide Receptor 2 (Npr2) by Phosphorylation of Juxtamembrane Serine and Threonine Residues Is Essential for Bifurcation of Sensory Axons.

Schmidt H, Dickey DM, Dumoulin A, Octave M, Robinson JW, Kühn R, Feil R, Potter LR, Rathjen FG.

J Neurosci. 2018 Nov 7;38(45):9768-9780. doi: 10.1523/JNEUROSCI.0495-18.2018. Epub 2018 Sep 24.

PMID:
30249793
3.

Dephosphorylation of the NPR2 guanylyl cyclase contributes to inhibition of bone growth by fibroblast growth factor.

Shuhaibar LC, Robinson JW, Vigone G, Shuhaibar NP, Egbert JR, Baena V, Uliasz TF, Kaback D, Yee SP, Feil R, Fisher MC, Dealy CN, Potter LR, Jaffe LA.

Elife. 2017 Dec 4;6. pii: e31343. doi: 10.7554/eLife.31343.

4.

Dephosphorylation is the mechanism of fibroblast growth factor inhibition of guanylyl cyclase-B.

Robinson JW, Egbert JR, Davydova J, Schmidt H, Jaffe LA, Potter LR.

Cell Signal. 2017 Dec;40:222-229. doi: 10.1016/j.cellsig.2017.09.021. Epub 2017 Sep 28.

5.

Skeletal overgrowth-causing mutations mimic an allosterically activated conformation of guanylyl cyclase-B that is inhibited by 2,4,6,-trinitrophenyl ATP.

Dickey DM, Otto NM, Potter LR.

J Biol Chem. 2017 Jun 16;292(24):10220-10229. doi: 10.1074/jbc.M117.780536. Epub 2017 Apr 27.

6.

A Glutamate-Substituted Mutant Mimics the Phosphorylated and Active Form of Guanylyl Cyclase-A.

Otto NM, McDowell WG, Dickey DM, Potter LR.

Mol Pharmacol. 2017 Jul;92(1):67-74. doi: 10.1124/mol.116.107995. Epub 2017 Apr 17.

7.

Catalytically Active Guanylyl Cyclase B Requires Endoplasmic Reticulum-mediated Glycosylation, and Mutations That Inhibit This Process Cause Dwarfism.

Dickey DM, Edmund AB, Otto NM, Chaffee TS, Robinson JW, Potter LR.

J Biol Chem. 2016 May 20;291(21):11385-93. doi: 10.1074/jbc.M115.704015. Epub 2016 Mar 15.

8.

Dephosphorylation of juxtamembrane serines and threonines of the NPR2 guanylyl cyclase is required for rapid resumption of oocyte meiosis in response to luteinizing hormone.

Shuhaibar LC, Egbert JR, Edmund AB, Uliasz TF, Dickey DM, Yee SP, Potter LR, Jaffe LA.

Dev Biol. 2016 Jan 1;409(1):194-201. doi: 10.1016/j.ydbio.2015.10.025. Epub 2015 Oct 30.

9.

Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature.

Wang SR, Jacobsen CM, Carmichael H, Edmund AB, Robinson JW, Olney RC, Miller TC, Moon JE, Mericq V, Potter LR, Warman ML, Hirschhorn JN, Dauber A.

Hum Mutat. 2015 Apr;36(4):474-81. doi: 10.1002/humu.22773. Epub 2015 Mar 16.

10.

Dephosphorylation and inactivation of NPR2 guanylyl cyclase in granulosa cells contributes to the LH-induced decrease in cGMP that causes resumption of meiosis in rat oocytes.

Egbert JR, Shuhaibar LC, Edmund AB, Van Helden DA, Robinson JW, Uliasz TF, Baena V, Geerts A, Wunder F, Potter LR, Jaffe LA.

Development. 2014 Sep;141(18):3594-604. doi: 10.1242/dev.112219.

11.

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma.

Buys ES, Potter LR, Pasquale LR, Ksander BR.

Front Mol Neurosci. 2014 May 19;7:38. doi: 10.3389/fnmol.2014.00038. eCollection 2014. Review.

12.

A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B.

Robinson JW, Dickey DM, Miura K, Michigami T, Ozono K, Potter LR.

Bone. 2013 Oct;56(2):375-82. doi: 10.1016/j.bone.2013.06.024. Epub 2013 Jul 1.

13.

Guanylyl cyclases A and B are asymmetric dimers that are allosterically activated by ATP binding to the catalytic domain.

Robinson JW, Potter LR.

Sci Signal. 2012 Sep 4;5(240):ra65. doi: 10.1126/scisignal.2003253.

14.

A functional screen provides evidence for a conserved, regulatory, juxtamembrane phosphorylation site in guanylyl cyclase a and B.

Yoder AR, Robinson JW, Dickey DM, Andersland J, Rose BA, Stone MD, Griffin TJ, Potter LR.

PLoS One. 2012;7(5):e36747. doi: 10.1371/journal.pone.0036747. Epub 2012 May 9.

15.

Luteinizing hormone reduces the activity of the NPR2 guanylyl cyclase in mouse ovarian follicles, contributing to the cyclic GMP decrease that promotes resumption of meiosis in oocytes.

Robinson JW, Zhang M, Shuhaibar LC, Norris RP, Geerts A, Wunder F, Eppig JJ, Potter LR, Jaffe LA.

Dev Biol. 2012 Jun 15;366(2):308-16. doi: 10.1016/j.ydbio.2012.04.019. Epub 2012 Apr 21.

16.

Guanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte.

Dickey DM, Dries DL, Margulies KB, Potter LR.

J Mol Cell Cardiol. 2012 Mar;52(3):727-32. doi: 10.1016/j.yjmcc.2011.11.007. Epub 2011 Nov 22.

17.

Guanylyl cyclase structure, function and regulation.

Potter LR.

Cell Signal. 2011 Dec;23(12):1921-6. doi: 10.1016/j.cellsig.2011.09.001. Epub 2011 Sep 10. Review.

18.

ATP potentiates competitive inhibition of guanylyl cyclase A and B by the staurosporine analog, Gö6976: reciprocal regulation of ATP and GTP binding.

Robinson JW, Potter LR.

J Biol Chem. 2011 Sep 30;286(39):33841-4. doi: 10.1074/jbc.M111.273565. Epub 2011 Aug 2.

19.

ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency.

Dickey DM, Potter LR.

Clin Chem. 2011 Sep;57(9):1272-8. doi: 10.1373/clinchem.2011.169151. Epub 2011 Jul 18.

20.

Antibody tracking demonstrates cell type-specific and ligand-independent internalization of guanylyl cyclase a and natriuretic peptide receptor C.

Dickey DM, Flora DR, Potter LR.

Mol Pharmacol. 2011 Jul;80(1):155-62. doi: 10.1124/mol.110.070573. Epub 2011 Apr 15. Erratum in: Mol Pharmacol. 2017 Feb;91(2):157.

21.

Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation.

Dickey DM, Potter LR.

J Mol Cell Cardiol. 2011 Jul;51(1):67-71. doi: 10.1016/j.yjmcc.2011.03.013. Epub 2011 Apr 1.

22.

Natriuretic peptide metabolism, clearance and degradation.

Potter LR.

FEBS J. 2011 Jun;278(11):1808-17. doi: 10.1111/j.1742-4658.2011.08082.x. Epub 2011 Apr 7. Review.

23.

The indolocarbazole, Gö6976, inhibits guanylyl cyclase-A and -B.

Robinson JW, Lou X, Potter LR.

Br J Pharmacol. 2011 Sep;164(2b):499-506. doi: 10.1111/j.1476-5381.2011.01291.x.

24.

Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Potter LR.

Pharmacol Ther. 2011 Apr;130(1):71-82. doi: 10.1016/j.pharmthera.2010.12.005. Epub 2010 Dec 24. Review.

25.

Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response.

Ralat LA, Guo Q, Ren M, Funke T, Dickey DM, Potter LR, Tang WJ.

J Biol Chem. 2011 Feb 11;286(6):4670-9. doi: 10.1074/jbc.M110.173252. Epub 2010 Nov 22.

26.

Mass spectrometric identification of phosphorylation sites in guanylyl cyclase A and B.

Yoder AR, Stone MD, Griffin TJ, Potter LR.

Biochemistry. 2010 Nov 30;49(47):10137-45. doi: 10.1021/bi101700e. Epub 2010 Nov 8.

27.

Human B-type natriuretic peptide is not degraded by meprin A.

Dickey DM, Potter LR.

Biochem Pharmacol. 2010 Oct 1;80(7):1007-11. doi: 10.1016/j.bcp.2010.06.015. Epub 2010 Jun 23.

28.

Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.

Dickey DM, Barbieri KA, McGuirk CM, Potter LR.

Mol Pharmacol. 2010 Sep;78(3):431-5. doi: 10.1124/mol.110.066084. Epub 2010 Jun 8.

29.

Prolonged atrial natriuretic peptide exposure stimulates guanylyl cyclase-a degradation.

Flora DR, Potter LR.

Endocrinology. 2010 Jun;151(6):2769-76. doi: 10.1210/en.2009-1239. Epub 2010 Apr 9.

30.

Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide.

Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, Hall JL, Lerman A, Redfield MM, Potter LR, Burnett JC Jr, Simari RD.

Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11282-7. doi: 10.1073/pnas.0811851106. Epub 2009 Jun 18.

31.

A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation.

Dickey DM, Yoder AR, Potter LR.

J Biol Chem. 2009 Jul 17;284(29):19196-202. doi: 10.1074/jbc.M109.010777. Epub 2009 May 19.

32.

Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.

Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM.

Handb Exp Pharmacol. 2009;(191):341-66. doi: 10.1007/978-3-540-68964-5_15. Review.

33.

Novel bifunctional natriuretic peptides as potential therapeutics.

Dickey DM, Burnett JC Jr, Potter LR.

J Biol Chem. 2008 Dec 12;283(50):35003-9. doi: 10.1074/jbc.M804538200. Epub 2008 Oct 21.

34.

Reduced ability of C-type natriuretic peptide (CNP) to activate natriuretic peptide receptor B (NPR-B) causes dwarfism in lbab -/- mice.

Yoder AR, Kruse AC, Earhart CA, Ohlendorf DH, Potter LR.

Peptides. 2008 Sep;29(9):1575-81. doi: 10.1016/j.peptides.2008.04.020. Epub 2008 May 8.

35.

Adenine nucleotides decrease the apparent Km of endogenous natriuretic peptide receptors for GTP.

Antos LK, Potter LR.

Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1756-63. Epub 2007 Sep 11.

36.
37.

Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations.

Bryan PM, Xu X, Dickey DM, Chen Y, Potter LR.

Am J Physiol Renal Physiol. 2007 May;292(5):F1636-44. Epub 2007 Jan 30.

38.

A sensitive method for determining the phosphorylation status of natriuretic peptide receptors: cGK-Ialpha does not regulate NPR-A.

Bryan PM, Smirnov D, Smolenski A, Feil S, Feil R, Hofmann F, Lohmann S, Potter LR.

Biochemistry. 2006 Jan 31;45(4):1295-303.

PMID:
16430226
39.

Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature.

Olney RC, Bükülmez H, Bartels CF, Prickett TC, Espiner EA, Potter LR, Warman ML.

J Clin Endocrinol Metab. 2006 Apr;91(4):1229-32. Epub 2005 Dec 29.

PMID:
16384845
40.

Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.

Potter LR, Abbey-Hosch S, Dickey DM.

Endocr Rev. 2006 Feb;27(1):47-72. Epub 2005 Nov 16. Review.

PMID:
16291870
41.

"Corination" of the proANP converting enzyme.

Potter LR.

Cell Metab. 2005 Feb;1(2):88-90.

42.

Differential regulation of NPR-B/GC-B by protein kinase c and calcium.

Abbey-Hosch SE, Smirnov D, Potter LR.

Biochem Pharmacol. 2005 Sep 1;70(5):686-94.

PMID:
16005434
43.

ATP-independent activation of natriuretic peptide receptors.

Antos LK, Abbey-Hosch SE, Flora DR, Potter LR.

J Biol Chem. 2005 Jul 22;280(29):26928-32. Epub 2005 May 23.

44.

Phosphorylation-dependent regulation of the guanylyl cyclase-linked natriuretic peptide receptors.

Potthast R, Potter LR.

Peptides. 2005 Jun;26(6):1001-8. Epub 2005 Apr 15. Review.

PMID:
15911068
45.
47.

Calcium-dependent dephosphorylation mediates the hyperosmotic and lysophosphatidic acid-dependent inhibition of natriuretic peptide receptor-B/guanylyl cyclase-B.

Potthast R, Abbey-Hosch SE, Antos LK, Marchant JS, Kuhn M, Potter LR.

J Biol Chem. 2004 Nov 19;279(47):48513-9. Epub 2004 Sep 14.

48.

CNP, cardiac natriuretic peptide?

Potter LR.

Endocrinology. 2004 May;145(5):2129-30. No abstract available.

PMID:
15087437
49.

Sphingosine-1-phosphate inhibits C-type natriuretic peptide activation of guanylyl cyclase B (GC-B/NPR-B).

Abbey-Hosch SE, Cody AN, Potter LR.

Hypertension. 2004 May;43(5):1103-9. Epub 2004 Mar 22.

PMID:
15037564
50.

Spatiotemporal regulation of the two atrial natriuretic peptide receptors in testis.

Müller D, Mukhopadhyay AK, Speth RC, Guidone G, Potthast R, Potter LR, Middendorff R.

Endocrinology. 2004 Mar;145(3):1392-401. Epub 2003 Nov 20.

PMID:
14630722

Supplemental Content

Loading ...
Support Center